This is a case report of a 74-year-old woman with pancreatic adenocarcinoma with metastases to the peripancreatic retroperitoneal lymph nodes, liver, lungs, and left supraclavicular lymph node who is now over 11 years out from her original diagnosis of metastatic disease.
Median survival for patients with metastatic pancreatic adenocarcinoma is on the order of a mere 3 to 6 months. The following report of long-term survival of a patient with this devastating malignancy illustrates a highly unusual case study of hope, courage, and determination. It is the author’s hope that this report might in some way prove inspirational to patients battling this demoralizing disease and provide encouragement to those physicians who treat them. The concept of weekly “metronomic” dosing of chemotherapy is also discussed, as well as targeted therapy for the treatment of pancreatic carcinoma and other cancers…
Patients with metastatic pancreatic adenocarcinoma (PC) and cholangiocarcinoma (CC) have a poor prognosis, with median survivals of 3 to 6 months and poor quality of life. A weekly, “metronomic dosing” of chemotherapy allows for increased dose density and dose intensity, but with good tolerability, and can have anti-angiogenic effects.
Patients with metastatic pancreatic cancer have a dismal prognosis and poor quality of life. Weekly “metronomic dosing” of chemotherapy allows for increased dose density, dose intensity, and antiangiogenic effects, yet affords good tolerability, allowing for a better quality of life and perhaps improved survival.
We previously reported excellent results of weekly metronomic dosing of POLF for metastatic PC. We now report updated data of 26 patients who received at least 11 weeks of treatment with this POLF regimen.